lu af28996
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 29, 2018 (NCT03565094)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Dopamine D2 receptorAGONIST
DRD2 agonist
- Dopamine D1 receptorAGONIST
DRD1 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06337110 | Phase 1 | Apr 10, 2024 | Lundbeck |
| NCT06277609 | Phase 1 | Feb 27, 2024 | Lundbeck |
| NCT06004180 | Phase 1 | Sep 12, 2023 | Lundbeck |
| NCT04291859 | Phase 1 | Feb 26, 2020 | Lundbeck |
| NCT03565094 | Phase 1 | May 29, 2018 | Lundbeck |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Lundbeck | For profit | 5 | 5 | 1 | 2018 |
1 organizations
Page 1 / 1